Animal testing and its alternatives—the most important omics is economics
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
For a long time, the discussion about animal testing vs its alternatives centered on animal welfare. This was a static warfare, or at least a gridlock, where life scientists had to take a position and make their value choices and hardly anyone changed sides. Technical advances have changed the frontline somewhat, with in vitro and in silico methods gaining more ground. Only more recently has the economic view begun to have an impact: Many animal tests are simply too costly, take too long, and give misleading results. As an extension and update to previous articles in this series written a decade ago, we reanalyze the economic landscape of especially regulatory use of animal testing and this time also consider respective alternative tests. Despite some ambiguity and data gaps, which we have filled with crude estimates, a picture emerges of globally regulated industries that are subject to stark geographic and sectorial differences in regulation, which determine their corresponding animal use. Both animal testing and its alternatives are industries in their own right, offering remarkable business opportunities for biotech and IT companies as well as contract research organizations. In light of recent revelations as to the reproducibility and relevance issues of many animal tests, the economic consequences of incorrect results and the reasons for still maintaining often outdated animal test approaches are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the average cost of a single, 2-generation reproductive animal toxicity study worldwide is €318,295 and for Europe alone is €285,842 (45), or roughly $349,890 and $314,215, respectively.”
From Limitations of Animal Studies for Predicting Toxicity in Clinical Trials (2019) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using a database of more than 800,000 animal toxicity studies performed for 350 chemicals under rigorous guidelines, a reviewer found toxicity was repeatable just 70% of the time in the same species (45).”
From Limitations of Animal Studies for Predicting Toxicity in Clinical Trials (2019) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with the costs of in vitro testing, animal tests range from 1.5× to >30× as expensive (44,45).”
From Limitations of Animal Studies for Predicting Toxicity in Clinical Trials (2019) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation
Zhu, S.-H., Sun, J. Y., Bonnevie, E., Cummins, S. E., Gamst, A., Yin, L., & Lee, M. (2014) · Tobacco Control · doi:10.1136/tobaccocontrol-2014-051670 · Cited by 913
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Toxicology for the twenty-first century
Hartung, T. (2009) · Nature · doi:10.1038/460208a · Cited by 661
Farsalinos, K. E., & Polosa, R. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614524430 · Cited by 594
Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010
Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., Andersen, K. E., Angers-Loustau, A., Aptula, A., Bal-Price, A., et al. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0693-2 · Cited by 584
Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model
Browne, P., Judson, R. S., Casey, W. M., Kleinstreuer, N. C., & Thomas, R. S. (2015) · Environmental Science & Technology · doi:10.1021/acs.est.5b02641 · Cited by 276
Research works printed but not linked: 2
- Bottini, A. A., Alepee, N., De Silva, O. et al. (2008). Optimi- zation of the post-validation process. The report and recom- mendations of ECVAM workshop 67. Altern Lab Anim 36, 353-366.
- nrd3681 · DOI · Paper page
Cited by
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
“Using a database of more than 800,000 animal toxicity studies performed for 350 chemicals under rigorous guidelines, a reviewer found toxicity was repeatable just 70% of the time in the same species (45).”
BackgroundIngber, D. E. (2020) · Advanced Science · doi:10.1002/advs.202002030 · Cited by 277
Fedi, A., Vitale, C., Ponschin, G., Ayehunie, S., Fato, M., & Scaglione, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.028 · Cited by 229
Avoiding Regrettable Substitutions: Green Toxicology for Sustainable Chemistry
Maertens, A., Golden, E., & Härtung, T. (2021) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.0c09435 · Cited by 163
Innovative Human Three-Dimensional Tissue-Engineered Models as an Alternative to Animal Testing
Bédard, P., Gauvin, S., Ferland, K., Caneparo, C., Pellerin, È., Chabaud, S., & Bolduc, S. (2020) · Bioengineering · doi:10.3390/bioengineering7030115 · Cited by 158
Metadata
- Authors
- Meigs, L.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Meigs, Lucy
- Venue
- ALTEX
- Publisher
- ALTEX Edition
- Published
- 2018
- Volume
- 35
- Issue
- 3
- Pages
- 275-305
- ISSN
- 0946-7785 (ISSN-L)
- 1868-596X
- OpenAlex
- W2883962615
- Cited by
- 184
- References
- 62
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 32 · 2023: 30 · 2022: 31 · 2021: 25 · 2020: 20 · 2019: 8
- FWCI
- 19.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- ALTEX (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KOPS (University of Konstanz) (submittedVersion, cc-by)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Social Sciences › Law › Animal Law and Welfare
- Keywords
- animal experimentation, alternatives to animal testing, in vitro methods, in silico analysis, contract research organizations, biotechnology industry
- MeSH terms
- Animals, Animal Testing Alternatives, Animal Welfare, Humans, Research, Reproducibility of Results, Toxicity Tests, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.